Firebrick Pharma Investor Goodall Sees Voting Power Diluted After Private Placement

Firebrick Pharma Limited ( (AU:FRE) ) just unveiled an update.

Firebrick Pharma shareholder Stephen Francis Goodall and related entities have disclosed an unchanged holding of 31,038,290 fully paid ordinary shares, but their voting power has fallen from 12.43% to 10.90% following a dilutionary private placement completed on 31 March 2026. The notice details that the reduction in percentage interest is solely due to the expanded share base, clarifying that Goodall’s absolute shareholding remains the same while his relative influence on shareholder votes has been moderately diluted.

Biotech Design Pty Ltd and S & R Goodall Super Pty Ltd, entities controlled by Goodall, collectively account for the entire holding, with 30,326,472 and 711,818 shares respectively, underscoring his continuing role as a substantial holder in the company. The disclosure provides transparency around ownership structure and confirms that while Goodall’s proportional stake has decreased, his sizeable position and associated voting power continue to be significant for corporate governance and existing shareholders.

More about Firebrick Pharma Limited

Firebrick Pharma Limited operates in the pharmaceutical sector. The company focuses on developing and commercialising healthcare and biotech products, and attracts investment from specialist biotech-focused shareholders, indicating a market focus on medical and life sciences innovation.

Average Trading Volume: 91,873

Technical Sentiment Signal: Buy

Current Market Cap: A$18.37M

For a thorough assessment of FRE stock, go to TipRanks’ Stock Analysis page.